On February 16th, the BC Government announced $1 billion in funding for the new St. Paul’s Hospital, set to open in 2026 at 1002 Station Street. The business case for the new hospital has been approved by the government, cementing the future of the innovative facility to serve as model for hospital care in the province.
BC-CfE’s provincial BOOST Collaborative is following on the heels of the successful Vancouver-based BOOST Collaborative. BOOST is inspired by the made-in-BC Treatment as Prevention®¨ strategy and supports a Targeted Disease Elimination®¨ (TDE®¨ ) approach. This means using tools and strategies that have been proven through the work of the BC-CfE in curbing HIV transmissions. The TDE®¨ strategy can address contagious diseases and diseases with a social contagion factor, such as substance use disorders.
An HIV cure is not yet in sight; however, scientists are actively pursuing a number of strategies in the hopes of one day achieving this goal.
The kick-off for the Simon Fraser University (SFU) Presidential Dream Colloquium generated much energy and optimism around continued advocacy for individuals living with HIV in Vancouver and across Canada-with the goal in mind of seeing an end to AIDS. However, Dr. Julio Montaner, BC-CfE Executive Director and Physician-in-Chief, warned there is a strong possibility for HIV to see a global resurgence if world leaders become complacent.
BC’s health care system is entering unchartered territory with the evolution of the HIV epidemic. According to the BC-CfE, one in two people on HIV treatment in BC are age 50 or older, compared with one in 10 two decades earlier. This means people with HIV are living to ages where seniors’ facilities become part of their health-care trajectory.
Saskatchewan primary-care physician has a simple message for doctors who are thinking of expanding their capacity to care for people with HIV. “Do it!” said Dr. Laura Marshall, a La Ronge family physician.
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below
